Epigenetics Modulators as Therapeutics for Neurological Disorders.

IF 2.8 4区 医学 Q2 PHARMACOLOGY & PHARMACY Current pharmaceutical design Pub Date : 2025-01-01 DOI:10.2174/0113816128330087241030093112
Mansi Gaba, Ashwani Sharma, Nitin Chitranshi, Girish Kumar, Reshu Virmani, Tarun Virmani, Dalapathi Gugulothu
{"title":"Epigenetics Modulators as Therapeutics for Neurological Disorders.","authors":"Mansi Gaba, Ashwani Sharma, Nitin Chitranshi, Girish Kumar, Reshu Virmani, Tarun Virmani, Dalapathi Gugulothu","doi":"10.2174/0113816128330087241030093112","DOIUrl":null,"url":null,"abstract":"<p><p>Epigenetics mechanisms play a crucial role in regulating gene expression and cellular function in the development and progression of neurological disorders. Emerging evidence suggests that dysregulation of these epigenetic processes contributes significantly to the pathogenesis of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and epilepsy. Epigenetic mechanisms, including DNA methylation, histone modification, and non-coding RNAs, significantly impact neural plasticity. The use of epigenetic modulators, including DNA methyltransferase and histone deacetylase inhibitors, offers a promising strategy to correct and modify aberrant epigenetic marks, potentially restoring neurological homeostasis. This review highlights recent research findings from ongoing clinical trials and the potential benefits and challenges of epigenetic therapies for neurological disorders. We discuss the capacity of these interventions to potentially halt or reverse disease progression, their targeted nature, and their neuroprotective effects. Additionally, we address the hurdles facing the field, including issues of specificity, delivery, and long-term efficacy.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":"1499-1520"},"PeriodicalIF":2.8000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical design","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113816128330087241030093112","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Epigenetics mechanisms play a crucial role in regulating gene expression and cellular function in the development and progression of neurological disorders. Emerging evidence suggests that dysregulation of these epigenetic processes contributes significantly to the pathogenesis of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and epilepsy. Epigenetic mechanisms, including DNA methylation, histone modification, and non-coding RNAs, significantly impact neural plasticity. The use of epigenetic modulators, including DNA methyltransferase and histone deacetylase inhibitors, offers a promising strategy to correct and modify aberrant epigenetic marks, potentially restoring neurological homeostasis. This review highlights recent research findings from ongoing clinical trials and the potential benefits and challenges of epigenetic therapies for neurological disorders. We discuss the capacity of these interventions to potentially halt or reverse disease progression, their targeted nature, and their neuroprotective effects. Additionally, we address the hurdles facing the field, including issues of specificity, delivery, and long-term efficacy.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
表观遗传学调节剂作为神经系统疾病的治疗手段。
表观遗传学机制在神经系统疾病的发生和发展中调控基因表达和细胞功能起着至关重要的作用。新出现的证据表明,这些表观遗传过程的失调对各种神经系统疾病的发病机制有重要作用,包括阿尔茨海默病、帕金森病和癫痫。表观遗传机制,包括DNA甲基化、组蛋白修饰和非编码rna,显著影响神经可塑性。表观遗传调节剂的使用,包括DNA甲基转移酶和组蛋白去乙酰化酶抑制剂,为纠正和修饰异常的表观遗传标记提供了一种有前途的策略,可能恢复神经稳态。本综述重点介绍了正在进行的临床试验的最新研究成果以及表观遗传治疗神经疾病的潜在益处和挑战。我们讨论了这些干预措施可能阻止或逆转疾病进展的能力,它们的靶向性,以及它们的神经保护作用。此外,我们还解决了该领域面临的障碍,包括特异性、递送和长期疗效问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.30
自引率
0.00%
发文量
302
审稿时长
2 months
期刊介绍: Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field. Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
期刊最新文献
Therapeutic Potential of Stem Cells in the Treatment and Management of Immunomodulatory Disorders. Reshaping the Future of MASLD - From Pathophysiological Mechanisms to New Therapeutic Horizons. Exosomes in Osteoarthritis: Emerging Roles in Pathogenesis, Diagnosis, and Therapeutic Potential. Novel Drug Delivery Systems for the Management of Vulvovaginal Candidiasis: Enhancing Therapeutic Efficacy. Unveiling Heart Failure: Gender-Specific Insights and Innovations in Women's Cardiac Health.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1